Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 In Patients Undergoing Surgery

Follow us on Google News:
 Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 In Patients Undergoing Surgery
Image source: ©2022 Kalkine Media®

Dec 8 (Reuters) - Baudax Bio Inc:


* BAUDAX BIO INITIATES PHASE II CLINICAL TRIAL EVALUATING BX1000 IN PATIENTS UNDERGOING SURGERY

* BAUDAX BIO INC- RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL WILL STUDY BX1000 IN ABOUT 80 ADULT PATIENTS

* BAUDAX BIO-TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN REPORTED IN FIRST GROUP OF PATIENTS ENROLLED, EFFICACY PARAMETERS HAVE BEEN RECORDED IN TRIAL

* BAUDAX BIO INC- TO ANNOUNCING COMPLETION OF PRE-PLANNED FIRST INTERIM ANALYSIS OF BX1000 PHASE 2 SURGERY TRIAL EARLY IN 2023

* BAUDAX BIO INC- TARGET TO COMPLETE FULL STUDY ENROLLMENT BY END OF MARCH, 2023 Source text for Eikon: Further company coverage:

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.